Japanese biotech Nxera Pharma (TSE: 4565) has received a $15 million payment from Neurocrine Biosciences (Nasdaq: NBIX) after ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

Swiss biotech iOnctura has appointed Steven Sciuto as chief financial officer and Michelle Tsai as chief operating officer, ...

Discover how gene editing and lab-grown meat are revolutionising healthcare and food in 2025, offering personalised ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

At the recent F&A Next conference in Wageningen, the Feike Sijbesma Sustainable Innovation Award 2025 was granted to two ...

New Orleans biotech South Rampart Pharma advances non-opioid pain drug with $8M funding from Ochsner Ventures and Gulf South ...

A new project, co-led by Dr Joshua James and Professor Patrick Cai of the Manchester Institute of Biotechnology at The ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

Mark explains some of the regulation trends in the EU, compared with those in the USA and also shares his thoughts on what advances in biotech regulations we can expect to see in the next decade.